• 1\. Pathological diagnosis as malignant tumor of Intrahepatic Cholangiocarcinoma;

• 2\. According to the UICC/AJCC TNM staging system (8th edition, 2017), resectable subjects were classified as Ib-IIIb stages;

• 3\. aged ≥ 18 years at the time of signing the Informed consent form (ICF);

• 4\. Expected survival time\>3 months;

• 5\. Both men and women are eligible;

• 6\. The patient's Eastern Oncology Collaborative Group (ECOG) physical condition score is 0 or 1;

• 7\. No serious complications, such as hypertension, coronary heart disease, or history of mental illness, and no history of severe allergies; Non pregnancy and non lactation period;

• 8\. The organ and blood system functions of the subjects meet the following requirements:

‣ Absolute neutrophil count (ANC) ≥ 1.5 × 10 \^ 9/L;

⁃ Platelet count ≥ 75 × 10 \^ 9/L;

⁃ Hemoglobin ≥ 90 g/L;

⁃ Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN);

⁃ Aspartate aminotransferase (AST) and alanine aminotransferase ≤ 2.5 x ULN;

⁃ Albumin ≥ 3g/dL

⁃ Creatinine ≤ 1.5 x ULN

• 9\. The subjects can understand and sign the informed consent form to participate in the experimental study; Good compliance.

• 10\. Participants who have not undergone any local or systemic treatment for tumors in the past, and have undergone radical resection surgery for biliary tract cancer before recurrence for at least 2 years, can be included;

• 11\. Subjects with potential fertility need to use a medically approved contraceptive measure (such as an intrauterine device, contraceptive pill, or condom) during the study treatment period and within one month after the end of the study treatment period; And within 72 hours before enrollment, the serum or urine HCG test must be negative and must be non lactating;